siRNA versus miRNA as therapeutics for gene silencing

Molecular Therapy Nucleic Acids

Volumn 4, Issue 9, 2015, Pages e252-

  Lam, Jenny K W ^a,b   Chow, Michael Y T ^a   Zhang, Yu ^a   Leung, Susan W S ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer therapy; Gene silencing; MicroRNA; RNA interference; Small interfering RNA

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ATELOCOLLAGEN; CHITOSAN; DENDRIMER; HYALURONIC ACID; LIPOPLEX; LOCKED NUCLEIC ACID; MICRORNA; MICROSPHERE; POLYAMIDOAMINE; SMALL INTERFERING RNA; UNTRANSLATED RNA; VIRUS VECTOR;

CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); DNA MODIFICATION; GENE SILENCING; GENE TARGETING; HUMAN; LOCAL THERAPY; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA STRUCTURE;

EID: 84954441161     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.23     Document Type: Review

References (218)

1. Mattick, JS and Makunin, IV (2006). Non-coding RNA. Hum Mol Genet 15 Spec No 1: R17-R29.
2. Tabernero, J, Shapiro, GI, LoRusso, PM, Cervantes, A, Schwartz, GK, Weiss, GJ et al. (2013). First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3: 406-417.
3. Schultheis, B, Strumberg, D, Santel, A, Vank, C, Gebhardt, F, Keil, O et al. (2014). First-inhuman phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 32: 4141-4148.
4. Bader, AG, Brown, D, Stoudemire, J and Lammers, P (2011). Developing therapeutic microRNAs for cancer. Gene Ther 18: 1121-1126.
5. DeVincenzo, J, Lambkin-Williams, R, Wilkinson, T, Cehelsky, J, Nochur, S, Walsh, E et al. (2010). A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107: 8800-8805.
6. Chandra, PK, Kundu, AK, Hazari, S, Chandra, S, Bao, L, Ooms, T et al. (2012). Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther 20: 1724-1736.
7. Sendi, H, Mehrab-Mohseni, M, Foureau, DM, Ghosh, S, Walling, TL, Steuerwald, N et al. (2015). MiR-122 decreases HCV entry into hepatocytes through binding to the 3'UTR of OCLN mRNA. Liver Int 35: 1315-1323.
8. Daka, A and Peer, D (2012). RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev 64: 1508-1521.
9. Behlke, MA (2006). Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670.
10. van Rooij, E, Purcell, AL and Levin, AA (2012). Developing microRNA therapeutics. Circ Res 110: 496-507.
11. Bader, AG, Brown, D and Winkler, M (2010). The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030.
12. Weiler, J, Hunziker, J and Hall, J (2006). Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 13: 496-502.
13. Broderick, JA and Zamore, PD (2011). MicroRNA therapeutics. Gene Ther 18: 1104-1110.
14. van Rooij, E and Kauppinen, S (2014). Development of microRNA therapeutics is coming of age. EMBO Mol Med 6: 851-864.
15. Deng, Y, Wang, CC, Choy, KW, Du, Q, Chen, J, Wang, Q et al. (2014). Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538: 217-227.
16. Agrawal, N, Dasaradhi, PV, Mohmmed, A, Malhotra, P, Bhatnagar, RK and Mukherjee, SK (2003). RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67: 657-685.
17. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
18. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
19. Pecot, CV, Calin, GA, Coleman, RL, Lopez-Berestein, G and Sood, AK (2011). RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67.
20. Gantier, MP and Williams, BR (2007). The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 18: 363-371.
21. Barik, S (2005). Silence of the transcripts: RNA interference in medicine. J Mol Med (Berl) 83: 764-773.
22. Sledz, CA, Holko, M, de Veer, MJ, Silverman, RH and Williams, BR (2003). Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839.
23. Bridge, AJ, Pebernard, S, Ducraux, A, Nicoulaz, AL and Iggo, R (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34: 263-264.
24. Rao, DD, Vorhies, JS, Senzer, N and Nemunaitis, J (2009). siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61: 746-759.
25. Kim, DH and Rossi, JJ (2007). Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184.
26. Kubowicz, P, Żelaszczyk, D and Pękala, E (2013). RNAi in clinical studies. Curr Med Chem 20: 1801-1816.
27. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
28. Lee, RC, Feinbaum, RL and Ambros, V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854.
29. Ha, M and Kim, VN (2014). Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15: 509-524.
30. Elbashir, SM, Lendeckel, W and Tuschl, T (2001). RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200.
31. Valencia-Sanchez, MA, Liu, J, Hannon, GJ and Parker, R (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524.
32. Bartel, DP (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
33. Lim, LP, Lau, NC, Garrett-Engele, P, Grimson, A, Schelter, JM, Castle, J et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
34. Shin, C, Nam, JW, Farh, KK, Chiang, HR, Shkumatava, A and Bartel, DP (2010). Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 38: 789-802.
35. Chi, SW, Hannon, GJ and Darnell, RB (2012). An alternative mode of microRNA target recognition. Nat Struct Mol Biol 19: 321-327.
36. Huntzinger, E and Izaurralde, E (2011). Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110.
37. Kim, VN, Han, J and Siomi, MC (2009). Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139.
38. Perwitasari, O, Bakre, A, Tompkins, SM and Tripp, RA (2013). siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) 6: 124-160.
39. Drosopoulos, K and Linardopoulos, S (2013). Integration of RNAi and small molecule screens to identify targets for drug development. Methods Mol Biol 986: 97-104.
40. Hayes, J, Peruzzi, PP and Lawler, S (2014). MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20: 460-469.
41. Walton, SP, Wu, M, Gredell, JA and Chan, C (2010). Designing highly active siRNAs for therapeutic applications. FEBS J 277: 4806-4813.
42. Kim, DH, Behlke, MA, Rose, SD, Chang, MS, Choi, S and Rossi, JJ (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23: 222-226.
43. Siolas, D, Lerner, C, Burchard, J, Ge, W, Linsley, PS, Paddison, PJ et al. (2005). Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23: 227-231.
44. Hefner, E, Clark, K, Whitman, C, Behlke, MA, Rose, SD, Peek, AS et al. (2008). Increased potency and longevity of gene silencing using validated Dicer substrates. J Biomol Tech 19: 231-237.
45. Chaudhary, A, Srivastava, S and Garg, S (2011). Development of a software tool and criteria evaluation for efficient design of small interfering RNA. Biochem Biophys Res Commun 404: 313-320.
46. Zhong, R, Kim, J, Kim, HS, Kim, M, Lum, L, Levine, B et al. (2014). Computational detection and suppression of sequence-specific off-target phenotypes from whole genome RNAi screens. Nucleic Acids Res 42: 8214-8222.
47. Meister, G (2013). Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 14: 447-459.
48. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216.
49. Schwarz, DS, Tomari, Y and Zamore, PD (2004). The RNA-induced silencing complex is a Mg2+-dependent endonuclease. Curr Biol 14: 787-791.
50. Angart, P, Vocelle, D, Chan, C and Walton, SP (2013). Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals (Basel) 6: 440-468.
51. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
52. Petri, S and Meister, G (2013). siRNA design principles and off-target effects. Methods Mol Biol 986: 59-71.
53. Reynolds, A, Leake, D, Boese, Q, Scaringe, S, Marshall, WS and Khvorova, A (2004). Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330.
54. Wang, X, Wang, X, Varma, RK, Beauchamp, L, Magdaleno, S and Sendera, TJ (2009). Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res 37: e152.
55. Kurreck, J (2006). siRNA efficiency: structure or sequence-that is the question. J Biomed Biotechnol 2006: 83757.
56. Tafer, H, Ameres, SL, Obernosterer, G, Gebeshuber, CA, Schroeder, R, Martinez, J et al. (2008). The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 26: 578-583.
57. Birmingham, A, Anderson, E, Sullivan, K, Reynolds, A, Boese, Q, Leake, D et al. (2007). A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2: 2068-2078.
58. Ui-Tei, K, Naito, Y, Nishi, K, Juni, A and Saigo, K (2008). Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res 36: 7100-7109.
59. Fedorov, Y, Anderson, EM, Birmingham, A, Reynolds, A, Karpilow, J, Robinson, K et al. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA 12: 1188-1196.
60. Jackson, AL, Burchard, J, Schelter, J, Chau, BN, Cleary, M, Lim, L et al. (2006). Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187.
61. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57-67.
62. Scacheri, PC, Rozenblatt-Rosen, O, Caplen, NJ, Wolfsberg, TG, Umayam, L, Lee, JC et al. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 101: 1892-1897.
63. Saxena, S, Jónsson, ZO and Dutta, A (2003). Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 278: 44312-44319.
64. Doench, JG, Petersen, CP and Sharp, PA (2003). siRNAs can function as miRNAs. Genes Dev 17: 438-442.
65. Snøve, O Jr and Holen, T (2004). Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 319: 256-263.
66. Lin, X, Ruan, X, Anderson, MG, McDowell, JA, Kroeger, PE, Fesik, SW et al. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 33: 4527-4535.
67. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
68. Kittler, R, Surendranath, V, Heninger, AK, Slabicki, M, Theis, M, Putz, G et al. (2007). Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat Methods 4: 337-344.
69. Kozomara, A and Griffiths-Jones, S (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39(Database issue): D152-D157.
70. Naito, Y and Ui-Tei, K (2013). Designing functional siRNA with reduced off-target effects. Methods Mol Biol 942: 57-68.
71. Judge, AD, Sood, V, Shaw, JR, Fang, D, McClintock, K and MacLachlan, I (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462.
72. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102.
73. Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baffi, JZ et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
74. Heil, F, Hemmi, H, Hochrein, H, Ampenberger, F, Kirschning, C, Akira, S et al. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
75. Goodchild, A, Nopper, N, King, A, Doan, T, Tanudji, M, Arndt, GM et al. (2009). Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol 10: 40.
76. Bramsen, JB and Kjems, J (2013). Engineering small interfering RNAs by strategic chemical modification. Methods Mol Biol 942: 87-109.
77. Iorio, MV and Croce, CM (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
78. Terasawa, K, Shimizu, K and Tsujimoto, G (2011). Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers. J Nucleic Acids 2011: 131579.
79. Zhang, Y, Wang, Z and Gemeinhart, RA (2013). Progress in microRNA delivery. J Control Release 172: 962-974.
80. Fabbri, M, Paone, A, Calore, F, Galli, R and Croce, CM (2013). A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol 10: 169-174.
81. Layzer, JM, McCaffrey, AP, Tanner, AK, Huang, Z, Kay, MA and Sullenger, BA (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771.
82. Watts, JK, Deleavey, GF and Damha, MJ (2008). Chemically modified siRNA: tools and applications. Drug Discov Today 13: 842-855.
83. Lima, WF, Wu, H, Nichols, JG, Sun, H, Murray, HM and Crooke, ST (2009). Binding and cleavage specificities of human Argonaute2. J Biol Chem 284: 26017-26028.
84. Wang, Y, Sheng, G, Juranek, S, Tuschl, T and Patel, DJ (2008). Structure of the guide-strand-containing argonaute silencing complex. Nature 456: 209-213.
85. Bramsen, JB, Laursen, MB, Nielsen, AF, Hansen, TB, Bus, C, Langkjaer, N et al. (2009). A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 37: 2867-2881.
86. Chiu, YL and Rana, TM (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048.
87. Allerson, CR, Sioufi, N, Jarres, R, Prakash, TP, Naik, N, Berdeja, A et al. (2005). Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48: 901-904.
88. Prakash, TP, Allerson, CR, Dande, P, Vickers, TA, Sioufi, N, Jarres, R et al. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 48: 4247-4253.
89. Amarzguioui, M, Holen, T, Babaie, E and Prydz, H (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31: 589-595.
90. Odadzic, D, Bramsen, JB, Smicius, R, Bus, C, Kjems, J and Engels, JW (2008). Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. Bioorg Med Chem 16: 518-529.
91. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505.
92. Cekaite, L, Furset, G, Hovig, E and Sioud, M (2007). Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 365: 90-108.
93. Hamm, S, Latz, E, Hangel, D, Müller, T, Yu, P, Golenbock, D et al. (2010). Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215: 559-569.
94. Veedu, RN and Wengel, J (2010). Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 7: 536-542.
95. Elmén, J, Thonberg, H, Ljungberg, K, Frieden, M, Westergaard, M, Xu, Y et al. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33: 439-447.
96. Mook, OR, Baas, F, de Wissel, MB and Fluiter, K (2007). Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 6: 833-843.
97. Braasch, DA, Jensen, S, Liu, Y, Kaur, K, Arar, K, White, MA et al. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975.
98. Grünweller, A, Wyszko, E, Bieber, B, Jahnel, R, Erdmann, VA and Kurreck, J (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31: 3185-3193.
99. Hornung, V, Guenthner-Biller, M, Bourquin, C, Ablasser, A, Schlee, M, Uematsu, S et al. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
100. Laursen, MB, Pakula, MM, Gao, S, Fluiter, K, Mook, OR, Baas, F et al. (2010). Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 6: 862-870.
101. Vaish, N, Chen, F, Seth, S, Fosnaugh, K, Liu, Y, Adami, R et al. (2011). Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 39: 1823-1832.
102. Campbell, JM, Bacon, TA and Wickstrom, E (1990). Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 20: 259-267.
103. Eckstein, F (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24: 374-387.
104. Crooke, ST (1998). Vitravene-another piece in the mosaic. Antisense & Nucleic Acid Drug Development 8: vii-viii.
105. Braasch, DA, Paroo, Z, Constantinescu, A, Ren, G, Oz, OK, Mason, RP et al. (2004). Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14: 1139-1143.
106. Choung, S, Kim, YJ, Kim, S, Park, HO and Choi, YC (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 342: 919-927.
107. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
108. Jahns, H, Roos, M, Imig, J, Baumann, F, Wang, Y, Gilmour, R et al. (2015). Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs. Nat Commun 6: 6317.
109. Hall, AH, Wan, J, Shaughnessy, EE, Ramsay Shaw, B and Alexander, KA (2004). RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 32: 5991-6000.
110. Yin, H, Kanasty, RL, Eltoukhy, AA, Vegas, AJ, Dorkin, JR and Anderson, DG (2014). Non-viral vectors for gene-based therapy. Nat Rev Genet 15: 541-555.
111. Couto, LB and High, KA (2010). Viral vector-mediated RNA interference. Curr Opin Pharmacol 10: 534-542.
112. Kasar, S, Salerno, E, Yuan, Y, Underbayev, C, Vollenweider, D, Laurindo, MF et al. (2012). Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun 13: 109-119.
113. Kumar, MS, Erkeland, SJ, Pester, RE, Chen, CY, Ebert, MS, Sharp, PA et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903-3908.
114. Liu, YP, Vink, MA, Westerink, JT, Ramirez de Arellano, E, Konstantinova, P, Ter Brake, O et al. (2010). Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA 16: 1328-1339.
115. Brandt, MR, Kirste, AG, Pozzuto, T, Schubert, S, Kandolf, R, Fechner, H et al. (2013). Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication. Virus Res 176: 155-160.
116. Esquela-Kerscher, A and Slack, FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
117. Lou, W, Chen, Q, Ma, L, Liu, J, Yang, Z, Shen, J et al. (2013). Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med (Berl) 91: 715-725.
118. Borel, F, Kay, MA and Mueller, C (2014). Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 22: 692-701.
119. Kota, J, Chivukula, RR, O'Donnell, KA, Wentzel, EA, Montgomery, CL, Hwang, HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
120. Stanek, LM, Sardi, SP, Mastis, B, Richards, AR, Treleaven, CM, Taksir, T et al. (2014). Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther 25: 461-474.
121. Hendrickx, R, Stichling, N, Koelen, J, Kuryk, L, Lipiec, A and Greber, UF (2014). Innate immunity to adenovirus. Hum Gene Ther 25: 265-284.
122. Baum, C, Kustikova, O, Modlich, U, Li, Z and Fehse, B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
123. Pauwels, K, Gijsbers, R, Toelen, J, Schambach, A, Willard-Gallo, K, Verheust, C et al. (2009). State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 9: 459-474.
124. Seow, Y and Wood, MJ (2009). Biological gene delivery vehicles: beyond viral vectors. Mol Ther 17: 767-777.
125. Movahedi, F, Hu, RG, Becker, DL and Xu, C (2015). Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics. Nanomedicine 11: 1575-1584.
126. Videira, M, Arranja, A, Rafael, D and Gaspar, R (2014). Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems. Nanomedicine 10: 689-702.
127. Williford, JM, Wu, J, Ren, Y, Archang, MM, Leong, KW and Mao, HQ (2014). Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16: 347-370.
128. Lv, H, Zhang, S, Wang, B, Cui, S and Yan, J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109.
129. Neuberg, P and Kichler, A (2014). Recent developments in nucleic acid delivery with polyethylenimines. Adv Genet 88: 263-288.
130. Höbel, S and Aigner, A (2013). Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5: 484-501.
131. Urban-Klein, B, Werth, S, Abuharbeid, S, Czubayko, F and Aigner, A (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466.
132. Dufès, C, Uchegbu, IF and Schätzlein, AG (2005). Dendrimers in gene delivery. Adv Drug Deliv Rev 57: 2177-2202.
133. Shcharbin, D, Shakhbazau, A and Bryszewska, M (2013). Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opin Drug Deliv 10: 1687-1698.
134. Kala, S, Mak, AS, Liu, X, Posocco, P, Pricl, S, Peng, L et al. (2014). Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer. J Med Chem 57: 2634-2642.
135. Liu, C, Liu, X, Rocchi, P, Qu, F, Iovanna, JL and Peng, L (2014). Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo. Bioconjug Chem 25: 521-532.
136. Liu, X, Li, G, Su, Z, Jiang, Z, Chen, L, Wang, J et al. (2013). Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol Rep 29: 1387-1394.
137. Shah, V, Taratula, O, Garbuzenko, OB, Taratula, OR, Rodriguez-Rodriguez, L and Minko, T (2013). Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 19: 6193-6204.
138. Siu, KS, Chen, D, Zheng, X, Zhang, X, Johnston, N, Liu, Y et al. (2014). Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. Biomaterials 35: 3435-3442.
139. Chiou, GY, Cherng, JY, Hsu, HS, Wang, ML, Tsai, CM, Lu, KH et al. (2012). Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release 159: 240-250.
140. Yang, YP, Chien, Y, Chiou, GY, Cherng, JY, Wang, ML, Lo, WL et al. (2012). Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33: 1462-1476.
141. Yhee, JY, Song, S, Lee, SJ, Park, SG, Kim, KS, Kim, MG et al. (2015). Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release 198: 1-9.
142. Deng, X, Cao, M, Zhang, J, Hu, K, Yin, Z, Zhou, Z et al. (2014). Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35: 4333-4344.
143. Yuan, Y, Makita, N, Cao, D, Mihara, K, Kadomatsu, K and Takei, Y (2015). Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects. Nucleic Acid Ther 25: 85-94.
144. Kawakami, E, Kawai, N, Kinouchi, N, Mori, H, Ohsawa, Y, Ishimaru, N et al. (2013). Local applications of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function. PLoS One 8: e64719.
145. Takeshita, F, Patrawala, L, Osaki, M, Takahashi, RU, Yamamoto, Y, Kosaka, N et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
146. Davis, ME and Brewster, ME (2004). Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3: 1023-1035.
147. Bartlett, DW and Davis, ME (2008). Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 99: 975-985.
148. Hu-Lieskovan, S, Heidel, JD, Bartlett, DW, Davis, ME and Triche, TJ (2005). Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992.
149. Murata, N, Takashima, Y, Toyoshima, K, Yamamoto, M and Okada, H (2008). Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release 126: 246-254.
150. Mountziaris, PM, Tzouanas, SN, Sing, DC, Kramer, PR, Kasper, FK and Mikos, AG (2012). Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation. Acta Biomater 8: 3552-3560.
151. Das, J, Das, S, Paul, A, Samadder, A, Bhattacharyya, SS and Khuda-Bukhsh, AR (2014). Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting S TAT 3 in lung cancer, in vitro and in vivo. Toxicol Lett 225: 454-466.
152. Bitar, A, Ahmad, NM, Fessi, H and Elaissari, A (2012). Silica-based nanoparticles for biomedical applications. Drug Discov Today 17: 1147-1154.
153. Steinbacher, JL and Landry, CC (2014). Adsorption and release of siRNA from porous silica. Langmuir 30: 4396-4405.
154. Chen, Y, Wang, X, Liu, T, Zhang, DS, Wang, Y, Gu, H et al. (2015). Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. Int J Nanomedicine 10: 2579-2594.
155. Tivnan, A, Orr, WS, Gubala, V, Nooney, R, Williams, DE, McDonagh, C et al. (2012). Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 7: e38129.
156. Chen, Y, Gu, H, Zhang, DS, Li, F, Liu, T and Xia, W (2014). Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials 35: 10058-10069.
157. Ozpolat, B, Sood, AK and Lopez-Berestein, G (2014). Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66: 110-116.
158. Wu, SY and McMillan, NA (2009). Lipidic systems for in vivo siRNA delivery. AAPS J 11: 639-652.
159. Liang, W and Lam, JKW. Endosomal escape pathways for non-viral nucleic acid delivery systems. In: Ceresa B (Ed.). Molecular Regulation of Endocytosis. InTech, 2012. pp. 429-456.
160. Wu, Y, Crawford, M, Mao, Y, Lee, RJ, Davis, IC, Elton, TS et al. (2013). Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol Ther Nucleic Acids 2: e84.
161. Zhang, Z, Tan, S and Feng, SS (2012). Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33: 4889-4906.
162. Kenjo, E, Asai, T, Yonenaga, N, Ando, H, Ishii, T, Hatanaka, K et al. (2013). Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. Biol Pharm Bull 36: 287-291.
163. Yang, ZZ, Li, JQ, Wang, ZZ, Dong, DW and Qi, XR (2014). Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35: 5226-5239.
164. Buyens, K, De Smedt, SC, Braeckmans, K, Demeester, J, Peeters, L, van Grunsven, LA et al. (2012). Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release 158: 362-370.
165. Shi, S, Han, L, Deng, L, Zhang, Y, Shen, H, Gong, T et al. (2014). Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release 194: 228-237.
166. Lobovkina, T, Jacobson, GB, Gonzalez-Gonzalez, E, Hickerson, RP, Leake, D, Kaspar, RL et al. (2011). In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano 5: 9977-9983.
167. Chen, Y, Zhu, X, Zhang, X, Liu, B and Huang, L (2010). Nanoparticles modified with tumortargeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
168. Chono, S, Li, SD, Conwell, CC and Huang, L (2008). An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 131: 64-69.
169. Ramezani, M, Khoshhamdam, M, Dehshahri, A and Malaekeh-Nikouei, B (2009). The influence of size, lipid composition and bilayer fluidity of cationic liposomes on the transfection efficiency of nanolipoplexes. Colloids Surf B Biointerfaces 72: 1-5.
170. Schäfer, J, Höbel, S, Bakowsky, U and Aigner, A (2010). Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials 31: 6892-6900.
171. Alshamsan, A, Hamdy, S, Samuel, J, El-Kadi, AO, Lavasanifar, A and Uludaʇ, H (2010). The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31: 1420-1428.
172. Jang, YL, Yun, UJ, Lee, MS, Kim, MG, Son, S, Lee, K et al. (2012). Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int J Pharm 434: 488-493.
173. Hong, J, Ku, SH, Lee, MS, Jeong, JH, Mok, H, Choi, D et al. (2014). Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials 35: 7562-7573.
174. Kim, WJ, Chang, CW, Lee, M and Kim, SW (2007). Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release 118: 357-363.
175. Ozcan, G, Ozpolat, B, Coleman, RL, Sood, AK and Lopez-Berestein, G (2015). Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87: 108-119.
176. Junn, E and Mouradian, MM (2012). MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 133: 142-150.
177. Mack, GS (2007). MicroRNA gets down to business. Nat Biotechnol 25: 631-638.
178. Li, T, Wu, M, Zhu, YY, Chen, J and Chen, L (2014). Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs. Nucleic Acid Ther 24: 302-312.
179. Obici, L and Merlini, G (2014). An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs 23: 1239-1251.
180. Sehgal, A, Barros, S, Ivanciu, L, Cooley, B, Qin, J, Racie, T et al. (2015). An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21: 492-497.
181. Barr, FA, Silljé, HH and Nigg, EA (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440.
182. Liu, X and Erikson, RL (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100: 5789-5794.
183. Shao, J, Zhou, B, Chu, B and Yen, Y (2006). Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6: 409-431.
184. Heidel, JD, Liu, JY, Yen, Y, Zhou, B, Heale, BS, Rossi, JJ et al. (2007). Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13: 2207-2215.
185. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
186. Zuckerman, JE, Gritli, I, Tolcher, A, Heidel, JD, Lim, D, Morgan, R et al. (2014). Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 111: 11449-11454.
187. Hicklin, DJ and Ellis, LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
188. Tao, W, South, VJ, Zhang, Y, Davide, JP, Farrell, L, Kohl, NE et al. (2005). Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8: 49-59.
189. Santel, A, Aleku, M, Röder, N, Möpert, K, Durieux, B, Janke, O et al. (2010). Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16: 5469-5480.
190. Aleku, M, Schulz, P, Keil, O, Santel, A, Schaeper, U, Dieckhoff, B et al. (2008). Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798.
191. Leenders, F, Möpert, K, Schmiedeknecht, A, Santel, A, Czauderna, F, Aleku, M et al. (2004). PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 23: 3303-3313.
192. Pereira, DM, Rodrigues, PM, Borralho, PM and Rodrigues, CM (2013). Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18: 282-289.
193. Bouchie, A (2013). First microRNA mimic enters clinic. Nat Biotechnol 31: 577.
194. Bader, AG (2012). miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 3: 120.
195. Aqeilan, RI, Calin, GA and Croce, CM (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
196. Guzman-Aranguez, A, Loma, P and Pintor, J (2013). Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol 170: 730-747.
197. Xu, S (2009). microRNA expression in the eyes and their significance in relation to functions. Prog Retin Eye Res 28: 87-116.
198. Lam, JK, Liang, W and Chan, HK (2012). Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 64: 1-15.
199. Zamora, MR, Budev, M, Rolfe, M, Gottlieb, J, Humar, A, Devincenzo, J et al. (2011). RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183: 531-538.
200. Chow, MYT and Lam, JKW. Dry powder formulation of plasmid DNA and siRNA for inhalation. Current Pharmaceutical Design, in press.
201. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
202. Lively, TN, Kossen, K, Balhorn, A, Koya, T, Zinnen, S, Takeda, K et al. (2008). Effect of chemically modified IL-13 short interfering RNA on development of airway hyperresponsiveness in mice. J Allergy Clin Immunol 121: 88-94.
203. Mostafa Anower, AK, Shim, JA, Choi, B and Sohn, S (2012). Pretreatment with interleukin-6 small interfering RNA can improve the survival rate of polymicrobial cecal ligation and puncture mice by down regulating interleukin-6 production. Eur J Pharmacol 688: 76-83.
204. Ibrahim, AF, Weirauch, U, Thomas, M, Grünweller, A, Hartmann, RK and Aigner, A (2011). MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224.
205. Lin, D, Cheng, Q, Jiang, Q, Huang, Y, Yang, Z, Han, S et al. (2013). Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo. Nanoscale 5: 4291-4301.
206. Shim, G, Choi, HW, Lee, S, Choi, J, Yu, YH, Park, DE et al. (2013). Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol Ther 21: 816-824.
207. Sakurai, Y, Hatakeyama, H, Akita, H and Harashima, H (2014). Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm 11: 2713-2719.
208. Akao, Y, Nakagawa, Y, Hirata, I, Iio, A, Itoh, T, Kojima, K et al. (2010). Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther 17: 398-408.
209. Trang, P, Wiggins, JF, Daige, CL, Cho, C, Omotola, M, Brown, D et al. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122.
210. Geisbert, TW, Hensley, LE, Kagan, E, Yu, EZ, Geisbert, JB, Daddario-DiCaprio, K et al. (2006). Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193: 1650-1657.
211. Shi, S, Han, L, Gong, T, Zhang, Z and Sun, X (2013). Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew Chem Int Ed Engl 52: 3901-3905.
212. DeVincenzo, J, Cehelsky, JE, Alvarez, R, Elbashir, S, Harborth, J, Toudjarska, I et al. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77: 225-231.
213. Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Basile, AS, Klamerus, KJ et al.; PF-04523655 Study Group. (2012). Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26: 1099-1105.
214. Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Klamerus, KJ, Chi-Burris, K et al.; MONET Clinical Study Group. (2012). Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 119: 1867-1873.
215. Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Basile, AS, Klamerus, KJ et al.; DEGAS Clinical Study Group. (2012). Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 53: 7666-7674.
216. Fitzgerald, K, Frank-Kamenetsky, M, Shulga-Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE et al. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68.
217. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
218. Leachman, SA, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM et al. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18: 442-446.